Multicentre, Prospective, Open, Non-interventional Study to Evaluate the Effect of Ovaleap® on the Pregnancy Rate and Clinical Effects as Well as the User-friendliness of the Ovaleap®-Pen in the Clinical Routine of the IVF- / ICSI-treatment.
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 30 Aug 2017
At a glance
- Drugs Follitropin alfa (Primary)
- Indications Female infertility
- Focus Therapeutic Use
- Sponsors Teva Pharmaceutical Industries
- 23 Aug 2017 Status changed from recruiting to active, no longer recruiting.
- 14 Mar 2017 Planned End Date changed from 1 Mar 2017 to 1 Mar 2018.
- 14 Mar 2017 Planned primary completion date changed from 1 Sep 2018 to 1 Dec 2017.